Drug Profile
Research programme: therapeutic vaccines - Pepscan/Immunovo
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pepscan Therapeutics
- Developer Immunovo; Pepscan Therapeutics
- Class Cancer vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Netherlands (Parenteral)
- 04 May 2010 Preclinical trials in Cancer in Netherlands (Parenteral)